A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
- Author(s)
- Agarwal, N; Azad, A; Carles, J; Chowdhury, S; McGregor, B; Merseburger, AS; Oudard, S; Saad, F; Soares, A; Benzaghou, F; Kerloeguen, Y; Kimura, A; Mohamed, N; Panneerselvam, A; Wang, F; Pal, S;
- Details
- Publication Year 2022-03,Volume 18,Issue #10,Page 1185-1198
- Journal Title
- Future Oncology
- Publication Type
- Protocol
- Abstract
- Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.
- Keywords
- Adenocarcinoma/*drug therapy/pathology; Androstenes/therapeutic use; Anilides/*therapeutic use; Antibodies, Monoclonal, Humanized/*therapeutic use; Antineoplastic Agents, Hormonal/*therapeutic use; Benzamides/therapeutic use; Humans; Immune Checkpoint Inhibitors/*therapeutic use; Male; Neoplasm Metastasis; Nitriles/therapeutic use; Phenylthiohydantoin/therapeutic use; Prostatic Neoplasms, Castration-Resistant/*drug therapy/pathology; Pyridines/*therapeutic use; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors; TAM kinase inhibitor; atezolizumab; cabozantinib; immune checkpoint inhibitor; metastatic castration-resistant prostate cancer; novel hormone therapy; phase III; receptor tyrosine kinase inhibitor; trial in progress
- Department(s)
- Medical Oncology
- PubMed ID
- 35034502
- Publisher's Version
- https://doi.org/10.2217/fon-2021-1096
- Open Access at Publisher's Site
https://doi.org/10.2217/fon-2021-1096- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-09-25 04:53:30
Last Modified: 2024-09-25 05:00:19